Your first look at the (possible) next FDA chief
Today Dr. Stephen Hahn, President Trump’s nominee to be FDA commissioner, will face his first test in Washington, appearing before the Senate health committee.
Unlike his predecessor, who had spent years opining on FDA policy from afar, Hahn has little in the way of a regulatory rap sheet. That means his views on drug development, opioids, vaping, and genome editing remain a mystery to the public.
And so we, like the senators on the committee, have some questions. Here's a dozen of them, covering public health, pharmaceutical policy, and regulating the cutting edge of science.
Unlike his predecessor, who had spent years opining on FDA policy from afar, Hahn has little in the way of a regulatory rap sheet. That means his views on drug development, opioids, vaping, and genome editing remain a mystery to the public.
And so we, like the senators on the committee, have some questions. Here's a dozen of them, covering public health, pharmaceutical policy, and regulating the cutting edge of science.
No hay comentarios:
Publicar un comentario